Advanced search
Publication Cover
Ocular Immunology and Inflammation Volume 27, 2019 - Issue 1
Submit an article Journal homepage
280
Views
34
CrossRef citations to date
0
Altmetric
Articles

Ten-Year Retention Rate of Infliximab in Patients with Behçet’s Disease-Related Uveitis

Claudia FabianiDepartment of Ophthalmology, Humanitas Clinical and Research Center, Rozzano (Milan), Italy
, MD, PhD,
Jurgen SotaResearch Center of Systemic Autoinflammatory Diseases and Behçet’s Disease and Rheumatology-Ophthalmology Collaborative Uveitis Center, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, Italy
, MD,
Antonio VitaleResearch Center of Systemic Autoinflammatory Diseases and Behçet’s Disease and Rheumatology-Ophthalmology Collaborative Uveitis Center, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, Italy
, MD,
Giacomo EmmiDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy
, MD, PhD,
Lorenzo VannozziDepartment of Surgery and Translational Medicine, Eye Clinic, University of Florence, Florence, Italy.
, MD,
Daniela BacheriniDepartment of Surgery and Translational Medicine, Eye Clinic, University of Florence, Florence, Italy.
, MD, PhD,
Giuseppe LopalcoInterdisciplinary Department of Medicine, Rheumatology Unit, University of Bari, Bari, Italy
, MD,
Silvana GuerrieroDepartment of Ophthalmology and Otolaryngology, University of Bari, Bari, Italy
, MD,
Vincenzo VeneritoInterdisciplinary Department of Medicine, Rheumatology Unit, University of Bari, Bari, Italy
, MD,
Ida OrlandoResearch Center of Systemic Autoinflammatory Diseases and Behçet’s Disease and Rheumatology-Ophthalmology Collaborative Uveitis Center, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, Italy
, MD,
Rossella FranceschiniOphthalmology and Neurosurgery Department, University of Siena, Siena, Italy
, MD,
Fiorella FuscoOphthalmology and Neurosurgery Department, University of Siena, Siena, Italy
, MD,
Bruno FredianiResearch Center of Systemic Autoinflammatory Diseases and Behçet’s Disease and Rheumatology-Ophthalmology Collaborative Uveitis Center, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, Italy
, MD,
Mauro GaleazziResearch Center of Systemic Autoinflammatory Diseases and Behçet’s Disease and Rheumatology-Ophthalmology Collaborative Uveitis Center, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, Italy
, MD,
Florenzo IannoneInterdisciplinary Department of Medicine, Rheumatology Unit, University of Bari, Bari, Italy
, MD,
Gian Marco TosiOphthalmology and Neurosurgery Department, University of Siena, Siena, Italy
, MD, PhD &
Luca CantariniResearch Center of Systemic Autoinflammatory Diseases and Behçet’s Disease and Rheumatology-Ophthalmology Collaborative Uveitis Center, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, ItalyCorrespondence[email protected] [email protected]
ORCID Iconhttp://orcid.org/0000-0002-7352-1275
, MD, PhD ORCID Icon show all
Pages 34-39 | Received 16 Jul 2017, Accepted 09 Oct 2017, Published online: 03 Nov 2017
 
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days

ABSTRACT

Purpose: To evaluate the 10-year drug retention rate of infliximab (IFX) in Behçet’s disease (BD)-related uveitis, the effect of a concomitant use of disease modifying anti-rheumatic drugs (DMARDs) on drug survival and differences according to the lines of biologic treatment.

Methods: Cumulative survival rates were studied using the Kaplan-Meier plot, while the Log-rank (Mantel-Cox) test was used to compare survival curves.

Results: Forty patients (70 eyes) were eligible for analysis. The drug retention rates at 12-, 24-, 60- and 120-month follow-up were 89.03%, 86.16%, 75.66% and 47.11% respectively. No differences were identified according to the use of concomitant DMARDs (p = 0.20), while a statistically significant difference was observed in relation to the different lines of IFX treatment (p = 0.014). Visual acuity improved from baseline to the last follow-up visit (p = 0.047) and a corticosteroid-sparing effect was observed (p < 0.0001).

Conclusions: IFX retention rate in BD-uveitis is excellent and is not affected by concomitant DMARDs.

Declaration of interest

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

Log in via your institution

Access through your institution

Log in to Taylor & Francis Online

Restore content access

Restore content access for purchases made as guest
Purchase options * Save for later

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 815.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.